Finance

Lists
Q2 2027 earnings • released • EPS beat +4,44% • Revenue beat +7,71%
See results
GLAND:NSE
Gland Pharma Ltd
3 288,60 INR
-0,42%
(-13,80) 1D
11-ноя., 14:29:25 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for GLAND...
Open
3 344,60 INR
High
3 370,50 INR
Low
3 272,00 INR
Mkt. cap
542,65 млд
Avg. vol.
469,30 миң
Volume
401,71 миң
Dividend
0,61%
Quarterly dividend
5,00 INR
Ex-dividend date
2026-ж., 11-авг.
P/E ratio
43,93
52-wk high
3 374,00 INR
52-wk low
1 573,60 INR
EPS
74,86 INR
No. of employees
4 миң
Open
3 344,60 INR
High
3 370,50 INR
Low
3 272,00 INR
Mkt. cap
542,65 млд
Avg. vol.
469,30 миң
Volume
401,71 миң
Dividend
0,61%
Quarterly dividend
5,00 INR
Ex-dividend date
2026-ж., 11-авг.
P/E ratio
43,93
52-wk high
3 374,00 INR
52-wk low
1 573,60 INR
EPS
74,86 INR
No. of employees
4 миң
News stories
From web sources and news partners
About Gland Pharma Ltd
CEOShyamakant Giri
Employees4,33 миң
Founded1978
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteglandpharma.com
Last report
2026-ж., 6-ноя.
Fiscal period
Q2 2027
17,62 INR / 16,87 INR
+4,44%beat
Revenue / Est. (INR)
19,03 млд / 17,66 млд
+7,71%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
16,95 млд
17,43 млд
18,00 млд
19,03 млд
Cost of goods sold
6,31 млд
8,32 млд
6,80 млд
7,30 млд
Cost of revenue
6,31 млд
8,32 млд
6,80 млд
7,30 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,24 млд
4,26 млд
4,44 млд
4,12 млд
Operating expense
7,37 млд
5,22 млд
7,42 млд
7,35 млд
Total operating expenses
13,68 млд
13,54 млд
14,22 млд
14,65 млд
Operating income
3,27 млд
3,89 млд
3,78 млд
4,38 млд
Other non operating income
631,73 млн
-1,79 млд
612,28 млн
-
EBT including unusual items
3,62 млд
5,06 млд
4,35 млд
4,31 млд
EBT excluding unusual items
3,86 млд
5,02 млд
4,35 млд
4,31 млд
Income tax expense
1,01 млд
1,39 млд
1,18 млд
1,40 млд
Effective tax rate
27,79%
27,51%
27,13%
32,53%
Other operating expenses
2,06 млд
-130,22 млн
1,87 млд
2,08 млд
Net income
2,61 млд
3,67 млд
3,17 млд
2,91 млд
Net profit margin
15,42%
21,04%
17,61%
15,28%
Earnings per share
16,98
22,23
19,22
17,62
Interest and investment income
-
2,06 млд
-
-
Interest expense
-39,30 млн
-63,09 млн
-43,61 млн
-71,38 млн
Net interest expenses
-39,30 млн
1,99 млд
-43,61 млн
-71,38 млн
Depreciation and amortization charges
1,08 млд
1,09 млд
1,11 млд
1,15 млд
EBITDA
4,17 млд
4,91 млд
4,80 млд
5,51 млд
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору